A cell-based drug delivery platform for treating central nervous system inflammation

A cell-based drug delivery platform for treating central nervous system inflammation

Mesenchymal stem cells (MSCs) are promising candidates for the development of cell-based drug delivery systems for autoimmune inflammatory diseases, such as multiple sclerosis (MS). Here, we investigated the effect of Ro-31-8425, an ATP-competitive kinase inhibitor, on the therapeutic properties of...

Full description

Bibliographic Details
Main Authors: Levy, Oren, Rothhammer, Veit, Mascanfroni, Ivan, Tong, Zhixiang, Kuai, Rui, De Biasio, Michael, Wang, Qingping, Majid, Tahir, Perrault, Christelle, Yeste, Ada, Kenison, Jessica E., Safaee, Helia, Musabeyezu, Juliet, Heinelt, Martina, Milton, Yuka, Kuang, Heidi, Lan, Haoyue, Siders, William, Multon, Marie-Christine, Rothblatt, Jonathan, Massadeh, Salam, Alaamery, Manal, Alhasan, Ali H., Quintana, Francisco J., Karp, Jeffrey Michael
Other Authors: Harvard University--MIT Division of Health Sciences and Technology
Format: Article
Language:English
Published: Springer Science and Business Media LLC 2021
Online Access:https://hdl.handle.net/1721.1/130518

Internet

https://hdl.handle.net/1721.1/130518

Similar Items